Trial Profile

Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS 15-2139)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary) ; Lenvatinib (Primary)
Indications Advanced breast cancer; Non-small cell lung cancer; Sarcoma; Solid tumours
Focus Therapeutic Use

Most Recent Events

04 Jun 2024 Results assessing safety and efficacy of lenvatinib and eribulin combination therapy presented at the 60th Annual Meeting of the American Society of Clinical Oncology
15 Apr 2024 Status changed from active, no longer recruiting to completed.
01 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Nov 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com